Combining Cell-Based Vaccine with Liver Cancer Treatment Shows Promise in Slowing Disease Progression
A new clinical trial reveals that integrating a dendritic cell-based vaccine with standard liver cancer treatments can significantly delay tumor progression, offering hope for improved patient outcomes.
A groundbreaking clinical trial has demonstrated that adding a dendritic cell-based vaccine to standard treatment can extend the time before liver cancer progresses. The study focused on patients with intermediate stage primary liver cancer who received a specialized vaccine derived from their own white blood cells. These cells were cultured in a lab with cancer-specific proteins to stimulate an immune response against the tumor. When combined with the established chemo-embolization therapy, patients who received the vaccine experienced a significantly longer tumor-free period—averaging 18 months—compared to just 10 months in those receiving only standard treatment.
This innovative approach was part of the ImmunoTACE trial, the first of its kind, which was led by the University of Birmingham and involved multiple institutions. The trial included 48 patients who were randomly assigned to receive either standard care alone or alongside the dendritic cell vaccine. Results showed a promising increase in progression-free survival, suggesting that this immunotherapy could become an effective adjunct in liver cancer treatment.
The vaccine works by using dendritic cells, which are crucial for initiating immune responses. In the lab, these cells are loaded with cancer antigens, enabling them to ‘teach’ the immune system to recognize and attack the tumor cells. Patients received vaccinations during standard chemo-embolization treatments and continued monthly doses for further support.
Dendritic cells are naturally present in the body but can become exhausted or suppressed within tumors. The vaccine aims to restore their function and enhance immune recognition of cancer cells. The study's lead author, Dr. Yuk Ting Ma, emphasized the potential of this therapy, highlighting its affordability and effectiveness. The findings suggest a promising new avenue for treating liver cancer, which remains one of the leading causes of cancer-related deaths worldwide.
Source: https://medicalxpress.com/news/2025-08-adding-cell-based-vaccine-liver.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Lymphoid-Derived Dendritic Cells Play a Key Role in Immune Regulation and Allergy Development
Scientists discover that lymphoid-derived dendritic cells are key players in immune suppression and allergy development, challenging previous beliefs about their origin and function. This breakthrough offers new potential targets for allergy and asthma therapies.
Unraveling the Molecular Causes of Long COVID Brain Fog
Recent research reveals increased AMPA receptor levels in the brains of long COVID patients with cognitive impairment, offering new insights into the condition's biological basis and potential therapies.
Early Neuroinflammation in Down Syndrome May Contribute to Higher Alzheimer’s Disease Risk
New research uncovers early neuroinflammation in young people with Down syndrome, providing insights into the high prevalence of Alzheimer’s disease and opening pathways for targeted therapies.